arrow
S

Shanshan Weng

Nanjing Normal University
H指数:20
被引数:1,509

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Einstein Probe Discovery of EP J182730.0−095633: A New Black Hole X-Ray Binary Candidate in Faint Outburst?

爱因斯坦探针发现EP J182730.0−095633:一个位于微弱耀发状态的新黑洞X射线双星候选体?

2025-09-250
OAAI
ROS-Responsive Hydrogel for Localized Delivery of Nampt and Stat3 Inhibitors Exhibits Synergistic Antitumor Effects in Colorectal Cancer Through Ferroptosis Induction and Immune Microenvironment Remodeling (Adv. Sci. 33/2025)

ROS响应性水凝胶用于局部递送Nampt和Stat3抑制剂,通过铁死亡诱导和免疫微环境重塑在结直肠癌中表现出协同抗肿瘤效果 (Adv. Sci. 33/2025)

2025-09-040
OAAI
ROS-Responsive Hydrogel for Localized Delivery of Nampt and Stat3 Inhibitors Exhibits Synergistic Antitumor Effects in Colorectal Cancer Through Ferroptosis Induction and Immune Microenvironment Remodeling

ROS响应性水凝胶通过铁死亡诱导和免疫微环境重塑,对局部递送Nampt和Stat3抑制剂在结直肠癌中表现出协同抗肿瘤效应

2025-06-100
OAAI
Einstein Probe Discovery of EP J005245.1-722843: A Rare Be-White Dwarf Binary in the Small Magellanic Cloud?

爱因斯坦探针发现EP J005245.1-722843:小麦哲伦云中的一颗稀有Be-白矮星双星?

2025-02-181
OA
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

Sintilimab联合贝伐单抗,奥沙利铂和卡培他滨作为RAS突变,微卫星稳定,不可切除的转移性结直肠癌的一线治疗: 一项开放标签,单臂,II期试验

2023-08-0112
OAAI
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

Sintilimab联合贝伐单抗和CapeOx (BBCAPX) 一线治疗RAS突变,微卫星稳定,转移性结直肠癌患者: 一项随机,开放标签,多中心研究的研究方案

2023-07-188
OAAI